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Abstract
AIM
To establish the impact of portal hypertension (PH) 
on wait-list/post-transplant outcomes in patients 
with polycystic liver disease (PCLD) listed for liver 
transplantation. 
METHODS
A retrospective single-centre case controlled study of 
consecutive patients listed for liver transplantation over 
12 years was performed from our centre. PH in the PCLD 
cohort was defined by the one or more of following 
parameters: (1) presence of radiological or endoscopic 
documented varices from our own centre or the referral 
centre; (2) splenomegaly (> 11 cm) on radiology in 
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ORIGINAL ARTICLE
Portal hypertension in polycystic liver disease patients does 
not affect wait-list or immediate post-liver transplantation 
outcomes
Case Control Study
Neil Rajoriya, Dhiraj Tripathi, Joanna A Leithead, Bridget K Gunson, Sophie Lord, James W Ferguson, 
Gideon M Hirschfield
absence of splenic cysts accounting for increased imaging 
size; (3) thrombocytopenia (platelets < 150 × 109/L); 
or (4) ascites without radiological evidence of hepatic 
venous outflow obstruction from a single cyst. 
RESULTS
Forty-seven PCLD patients (F: M = 42: 5) were listed 
for liver transplantation (LT) (single organ, n  = 35; 
combined liver-kidney transplantation, n  = 12) with 19 
patients (40.4%) having PH. When comparing the PH 
group with non-PH group, the mean listing age (PH 
group, 50.6 (6.4); non-PH group, 47.1 (7.4) years; P  
= 0.101), median listing MELD (PH group, 12; non-PH 
group, 11; P  = 0.422) median listing UKELD score (PH 
group, 48; non-PH group, 46; P  = 0.344) and need for 
renal replacement therapy (P  = 0.317) were similar. 
In the patients who underwent LT alone, there was no 
difference in the duration of ICU stay (PH, 3 d; non-PH, 
2 d; P  = 0.188), hospital stay length (PH, 9 d; non-PH, 
10 d; P  = 0.973), or frequency of renal replacement 
therapy (PH, 2/8; non-PH, 1/14; P  = 0.121) in the 
immediate post-transplantation period.  
CONCLUSION
Clinically apparent portal hypertension in patients with 
PCLD listed for liver transplantation does not appear 
to have a major impact on wait-list or peri-transplant 
morbidity.
Key words: Polycystic liver disease; Portal hypertension; 
Liver transplantation
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Clinically apparent portal hypertension is 
common in patients with polycystic liver disease, 
however it appears that this finding does not affect 
wait list or post-transplantation outcomes in the short-
term.
Rajoriya N, Tripathi D, Leithead JA, Gunson BK, Lord S, 
Ferguson JW, Hirschfield GM. Portal hypertension in polycystic 
liver disease patients does not affect wait-list or immediate post-
liver transplantation outcomes. World J Gastroenterol 2016; 
22(45): 9966-9973  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v22/i45/9966.htm  DOI: http://dx.doi.
org/10.3748/wjg.v22.i45.9966
INTRODUCTION
Polycystic liver disease (PCLD) is an autosomal 
dominant condition that has 2 forms - either occurring 
in isolated form or combined with cysts in extra-
hepatic organs[1,2]. Of those patients who have PCLD 
associated with extra-hepatic cysts, 80%-90% 
have renal cysts and can develop progressive renal 
impairment ultimately leading to end-stage renal 
failure (ESRF). In those with only polycystic kidney 
disease (PCKD) at initial diagnosis, 30% can thereafter 
develop liver cysts within 30 years of diagnosis[3]. 
Genetic mutations have been identified in patients 
with PCLD with downstream protein processing 
defects leading to proliferation in cyst-lining epithelia, 
fluid secretion into cysts, extracellular membrane re-
modelling around cysts and finally neovascularization 
of the cysts[4-8]. Eighty percent of patients can remain 
asymptomatic or present with mild abnormalities in 
liver function blood tests[9], whereas some patients 
can become symptomatic with enlargement of cysts 
and their mass/pressure effects on adjacent organs. 
Liver cysts can become infected with a mortality of 
2%[10] or even in rare cases rupture with severe pain, 
haemodynamic instability and/or rarely death.
Treatment options for PCLD can include medical 
therapies, interventional radiology, surgical fene-
stration/resection or liver transplantation (LT), whilst 
renal replacement therapy (RRT) or renal trans-
plantation can be performed for PCKD-associated 
ESRF in those with PCLD. Transplantation remains an 
effective curative treatment for PCLD and is indicated if 
disabling symptoms leading to decreased performance 
status or quality of life[11]. In the United states, LT for 
PCLD falls into the Model for End-stage Liver Disease 
(MELD) exception guidelines[12] whilst United Kingdom 
guidelines (NHSBT 2009:4.1.2.3) state that a LT 
can be performed in the PCLD setting if “intractable 
symptoms due to mass of liver or pain unresponsive 
to cystectomy, or severe complications secondary to 
portal hypertension”[13].
Development of portal hypertension (PH) in PCLD 
can be a significant concern in advanced disease 
manifested by splenomegaly, ascites [without nece-
ssarily signs of hepatic venous outflow obstruction 
(HVOO)] or variceal formation. PH in the context 
of PCLD was described in 35% of patients from a 
European cohort[14] and often can be notoriously 
difficult to treat[15], however the clinical course and 
outcome of such patients once listed for LT has not yet 
been clearly identified. The aim of this study was thus 
to establish the impact of clinically apparent PH on 
wait-list and immediate post-transplantation outcomes 
specifically in patients with PCLD listed for LT.
MATERIALS AND METHODS
A single centre retrospective study was performed in 
a LT centre (Queen Elizabeth Hospital, Birmingham, 
United Kingdom). The study protocol was approved 
by the Queen Elizabeth Hospital local clinical audit 
committee (Reference CAB:04870-12). Patients 
with PCLD listed consecutively over a 12-year period 
(January 2000 and December 2012) were included. All 
PCLD referred to our centre or undergoing follow-up 
(irrespective of transplantation or not) were identified 
from a pre-existing transplant database which included 
all parameters of listed patient’s illness, liver function, 
and if applicable listing criteria and operation/intensive 
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care unit (ICU) spell details (including data on blood 
product usage and follow-up). Details on nutritional 
status except listing weight were not routinely 
available.
The decision to start patients on RRT whilst on 
the waiting list was made by the local Nephrology 
team and decision to perform combined liver/kidney 
transplantation was made together by the Hepatology 
and Nephrology teams at a multi-disciplinary 
transplantation listing meeting. Patients were listed 
for LT based on symptoms after vigorous multi-
professional assessment process. Validated symptom 
questionnaires were not used as part of this study, 
rather cases were discussed on an individual basis by 
the clinical team during the transplantation assessment 
process. Symptoms were normally secondary to liver 
cysts causing intractable pain, poor quality of life, 
malnutrition, recurrent liver cyst infection, or those 
symptoms secondary to the development of PH. The 
transplant assessment process involved standard 
radiological assessment by the surgical team via 
Ultrasound (US), computed tomography (CT) and/or 
magnetic resonance imaging (MRI). Liver volumetric 
measurement data was not performed during this time 
period. 
PH in the PCLD cohort was defined by the one 
or more of following parameters: (1) presence 
of radiological or endoscopic documented varices 
from our own centre or the referral centre; (2) 
splenomegaly (> 11 cm) on US, CT or MRI in absence 
of radiological splenic cysts accounting for increased 
imaging size; (3) thrombocytopenia (platelets < 150 × 
109/L); or (4) ascites without radiological evidence of 
HVOO from a single cyst. Patients were assessed and 
listed for a combined kidney/liver transplant if they 
had concomitant ESRF with the main measurement of 
renal function being the estimated glomerular filtration 
rate (eGFR), determined using the Modification of 
Diet in Renal Disease Study 4-variable equation[16]. 
This was then confirmed with an isotopic GFR where 
required or recommended by the nephrology team. 
Chronic kidney disease (CKD) was defined as eGFR 
< 60 mL/min/1.73 m2 on at least 2 occasions and 
sustained[17]. 
Normally distributed continuous variables and 
non-parametric continuous variables were compared 
using the Student’s t-test and Mann-Whitney test, 
respectively. χ 2 analysis or Fisher’s exact test were 
used for comparison of categorical data. Patient 
survival after transplantation was estimated using 
Kaplan-Meier plots with log-rank test for differences. 
Patients were censored at time of last known follow-
up. Data was analysed using the SPSS 21 package 
(SPSS Inc, Chicago, IL, United States). All values are 
expressed as mean and standard deviation, median 
and inter-quartile range (IQR) and number and 
percent (%) as appropriate. P < 0.05 was considered 
statistically significant at all times.
RESULTS
Patient demographics and portal hypertension 
manifestations
A total of 75 patients were identified with PCLD 
attending our centre during the 12-year period. Of 
this overall cohort 32 patients (42.5%) had signs in 
keeping with clinically apparent PH. Of the overall 
cohort (n = 75), 47 patients (62.7%) were listed for 
LT (35 patients listed for single organ and 12 patients 
listed for combined liver/kidney). Of the 35 patients 
listed for single organ liver transplantation 15 had PH 
(42.9%) and of the 12 listed for combined liver/kidney 
transplant 4 had PH (33.3%) (P = 0.410). There were 
no differences in how PH was manifested between the 
groups (Table 1) irrespective if receiving a single organ 
liver transplant or combined liver/kidney transplant.
When comparing the PH group and those without 
(non-PH group - Table 2), at listing, baseline characte-
ristics were similar between the groups. Characteristics 
were similar with regards to age (PH 50.6 years, non-
PH 47.1 years, P = 0.101) and gender (P = 0.683). The 
patients’ liver synthetic function was similar between 
the PH group and non-PH groups (Bilirubin P = 0.965, 
INR P = 0.173) and United Kingdom Model for End-
Stage Liver Disease (UKELD) (PH 48, non-PH 46, P = 
0.344)/MELD scores (P = 0.344/PH 12, non-PH 11, 
P =0.422) were similar between the groups. 84.2% 
of patients with PH had CKD stage III-V compared to 
67.9% of patients without (P = 0.179). 19.2% and 7.1% 
of PH and non-PH patients were dialysis dependent 
respectively (P = 0.317).
Outcomes on the list
Thirty-four patients were transplanted by the time 
of data analysis (72.3%). Two patients with PH died 
prior to transplantation (sepsis and progressive liver 
disease) and 1 patient without PH (progressive liver 
disease). Of the remaining 10 patients not transplanted 
at time of data analysis, 9 were still active on the 
waiting list and 1 patient had been removed from the 
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Table 1  Comparison of features of portal hypertension 
between the groups requiring single liver transplant and 
those requiring combined liver/kidney transplant (note some 
patients had > 1 manifestation)
Single organ 
liver (n  = 15 
with portal 
HBP)
Combined 
liver/kidney (n  
= 4 with portal 
HBP)
P  value
Ascites 8 3 0.582
Varices1 1 0 0.745
Splenomegaly2 7 2 0.585
Thrombocytopenia3 3 2 0.379
1Confirmed endoscopically or radiologically on CT; 2Confirmed on 
imaging without evidence of splenic cysts; 3Platelet count < 150 × 109. 
HBP: Hypertension.
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PH group 2 d, P = 0.188) and hospital stay (PH group 
9 d; non-PH group 10 d, P = 0.973). There was no 
difference in frequency of RRT (PH group 2/8; non-PH 
group 1/14, P = 0.121) with similar observations made 
in the patients who underwent combined liver-kidney 
transplantation (data not shown). There were no 
differences found (in the single organ liver transplant 
or the combined liver/kidney group) when transfusion 
requirements were assessed between the PH groups 
and the non-PH groups (Tables 3 and 4). The duration 
of ICU spells post-transplantation were similar [3 d in 
PH group vs 2 d in non-PH group (P = 0.188)]. Also 
overall hospital stays were similar between the groups 
(9 d in PH group vs 10 d in non-PH group, P = 0.973).
DISCUSSION
Patients with PCLD can have variable courses of 
their disease with the majority of patients remaining 
asymptomatic. As the liver cysts grow, patients can 
start to develop symptoms due to local mass effect such 
as: right upper quadrant pain, early satiety and post-
prandial fullness (due to pressure effects on adjacent 
stomach). Patient can also develop shortness of breath 
(due to liver volume burden), and direct compression 
of the portal vein/inferior vena cava. Symptoms also 
may be due to complications of the cysts such as 
haemorrhage, infection or rupture. Treatment can 
be broadly divided into medical, radiological and 
surgical. Medical treatments include somatostatin 
analogues which reduce the secretion of fluid into 
the cysts and inhibit cholangiocyte proliferation[18-22] 
and have been shown to be effective in reducing liver 
volume when compared to placebo and effective in 
improving symptoms[23-25]. Radiological treatments can 
include interventional radiological arterial embolization 
or injection sclerotherapy of cysts, whilst surgical 
techniques include cysts fenestration, resection or 
transplantation. The choice of surgical technique often 
is dependent on factors such as: symptoms, cyst 
characteristics, volume of normal liver parenchyma and 
waiting list (as had declined a transplant after being 
listed). The median time from listing to transplantation 
for PH patients was 72 d (IQR 34-524) and for non-PH 
patients was 139 d (IQR 48-390) (P = 0.466).
In the single organ LT patients (n = 22), the 
median time from listing to transplantation for patients 
with PH was 49 d (IQR 16-426) compared to 139 d (IQR 
53-345) (P = 0.188) for patients in the non-PH group. 
In the combined liver/kidney transplant patients (n = 
12), the median time from listing to transplantation 
for PH patients was 289 d (IQR 58-551) and for 
those in the non-PH group 210 d (IQR 16-579) (P = 
0.933). Overall, when the length of time of the list was 
compared, there were no significant differences found 
in the median time on the list between the PH group (n 
= 12) [72 d (IQR 34-524)] and the non-PH group (n = 
22) [139 d (IQR 48-390), P = 0.466]. On follow up 3 
patients died on waiting list (2 with PH). 
ICU spells/requirements and hospital stays
In the patients who underwent LT alone, there was no 
difference in the duration of ICU (PH group 3 d; non-
Table 2  Comparison of patient demographics between 
patients with and without portal hypertension
Listing parameter Portal hypertension 
(n  = 19)
Non-portal 
hypertension 
(n  = 28)
P  value
Age (yr) 50.6 (6.4) 47.1 (7.4) 0.101
Female gender 17 (89.5) 25 (89.3) 0.683
Bilirubin (µmol/L)   8 (6-11)   8 (6-12) 0.965
INR    1.1 (1.0-1.2)    1.1 (1.0-1.1) 0.173
Creatinine (mmol/L)     106 (104-436)   119 (92-201) 0.508
Platelet count (× 109)     177 (147-242)     234 (198-242) 0.012
Sodium (mmol/l)     139 (137-143)     140 (138-142) 0.483
MELD score 12 (9-21) 11 (8-16) 0.422
UKELD score   48 (44-50)   46 (45-48) 0.344
Chronic kidney disease1 16 (84.2) 19 (67.9) 0.179
Dialysis dependant   3 (15.8) 2 (7.1) 0.317
1Chronic kidney disease defined as stage Ⅲ-Ⅴ[17]. INR: International 
normalized ratio; MELD: Model For End-stage Liver Disease; UKELD: 
United Kingdom Model for End-Stage Liver Disease.
Table 3  Intensive care unit requirements and hospital stay 
between the portal hypertensive and non-portal hypertensive 
groups in patients receiving a single organ liver transplant
Portal 
hypertensive 
group (n  = 8)
Non-portal 
hypertensive 
group (n  = 14)
P  value
Intra-operative
   RCC(units) 3 (1-4) 4 (2-7) 0.238
   FFP(units) 10 (1-18)   8 (7-14) 0.973
   Plts (units) 0   3 (0-10) 0.145
   ICU stay (d) 3 (3-4) 2 (2-4) 0.188
   Hospital stay (d)   9 (7-13) 10 (7-12) 0.973
   RRT in ICU 
   immediately post-op
2/8 (25%) 0/14 (0) 0.121
FFP: Fresh frozen plasma; ICU: Intensive care unit; Plts: Platelets; RCC: 
Red cell concentrate; RRT: Renal replacement therapy.
Table 4  Intensive care unit requirements and hospital stay 
between the portal hypertensive and non-portal hypertensive 
groups in patients receiving a combined liver/kidney transplant
Portal 
hypertensive 
group (n  = 4)
Non-portal 
hypertensive 
group (n  = 8)
P  value
Intra-operative
   RCC (units) 13 (4-19)   9 (3-19) 0.933
   FFP (units) 15 (7-23) 14 (5-18) 0.683
   Plts (units) 10 (3-10) 10 (0-20) 0.683
   ICU stay (d) 5 (3-7)   7 (3-41) 0.368
   Hospital stay (d)   16 (12-18)   15 (12-49) 0.808
   RRT in ICU 
   immediately post-op
3/4 (75%)  3/8 (37.5%) 0.273
FFP: Fresh frozen plasma; ICU: Intensive care unit; Plts: Platelets; RCC: 
Red cell concentrate; RRT: Renal replacement therapy.
Rajoriya N et al . Impact of portal hypertension in polycystic liver disease
9970 December 7, 2016|Volume 22|Issue 45|WJG|www.wjgnet.com
also patency of hepatic/portal veins - with the surgeons 
often using Schnelldorfer et al[26] or Gigot et al[27]’s 
classification to aid with decisions. LT remains an effective 
curative treatment for patients with PCLD with indications 
varying but indicated if decreased performance status 
or quality of life[11,28] then LT can be offered. LT has been 
shown to improve domains of quality of life in a series 
of 36 patients[29] with 11% of patients in this study 
having PH. Recent Australian national guidelines[30] 
summarised that treatment of liver cysts should be 
directed at reducing liver volume when the patients 
were highly symptomatic, with options including 
sclerotherapy, fenestration, segmental resection and 
transplantation (Level 1D evidence).
PH in chronic liver disease is the established key 
event leading to such complications such as ascites 
and variceal formation. PH results from mechanical 
obstruction due to fibrosis or regenerative nodules 
resulting in increased resistance to flow. In PCLD this 
may be the case secondary to flow distortion due to 
large cysts and thus their compressive effects leading 
to increased intrahepatic resistance. In cirrhosis and 
PH a hyperdynamic circulation develops in response 
to changes in haemodynamics, manifested as high 
cardiac output with low systematic vascular resistance 
and arterial hypotension[31]. In our centre portal 
pressure measurements are not routinely performed 
and could be deemed a criticism of this retrospective 
study however the technique to gain the hepatic 
venous pressure gradient (HVPG) measurement 
can indeed be difficult in patients with PCLD due to 
distorted anatomy[32] with lack of reporting of such 
measurements in other PCLD studies where PH has 
been assessed[14]. Varices in non-PCLD patients are 
more likely to develop if the HVPG is > 10 mmHg[33] 
however the role of HVPG measurements in the PCLD 
patient cohort requires further clarification in future 
studies. In young patients with PCLD who have early 
signs of PH, congenital hepatic fibrosis should also be 
considered as a potential cause of PH[34].
In our study we sought to explore if any differences 
in outcome in PCLD patients with PH once listed for LT 
to those who did not. To our knowledge our study is 
the 1st paper to analyse such subgroups in this manner 
in patients listed LT. The overall number of patients in 
such studies in PCLD has not been large and indeed 
those with PH described. In a review of 9 studies in 
patients with PCLD[35-43] a median of 8 patients (range 
3-17) was found - this compares to 47 patients listed 
for LT in our single-centre study. Mortality rates in the 
series studied ranged from 0%-50% on follow up and 
the number of patients with PH however was not clear. 
In one such multicenter study[14], 58 patients were 
pooled together from 75 centres via the European Liver 
and Intestinal Association (ELITA) - with 35% patients 
having PH (compared to 42.9% of patients listed for LT 
in our study - a single centre). By analysing in such a 
manner, we have established to seek if there was any 
difference in patients who had clinically apparent PH as 
a consequence of PCLD on their outcome once listed 
for transplantation. Ascites in the context of HVOO can 
be exudative due to high permeability of the dilated 
sinusoidal walls to proteins[44]. Patients with HVOO 
can also however present with transudative ascites, 
abdominal pain and hepatomegaly in 90%-96% of 
cases[34]. By taking established markers of clinically 
apparent PH and applying it to the PCLD cohort, we 
attempted to stratify the patients and assess for 
any differences in outcome once listed for LT. The 2 
groups appeared to be well matched patient groups 
at time of listing between the PH and non-PH groups 
especially when assessing their liver synthetic function 
(Table 2), again suggesting clearly the mechanism 
in developing PH in this cohort is different to those 
patients with cirrhosis who can develop PH and 
synthetic liver dysfunction with progressive disease. 
Patients with PCLD often have preserved liver function 
as reflected by low UKELD and MELD scores - thus 
PCLD patients fall within MELD[12] exception guidelines 
and also the variant syndrome United Kingdom listing 
criteria[13]. When comparing the groups who had single 
LT compared to those having a combined kidney/
liver transplant there appeared to be no significant 
differences in the type/manifestation of clinically 
apparent PH that these 2 groups had. The advent of 
PH importantly did not appear to affect the immediate 
post-transplantation course of the patients, with 
similar requirement for blood product use between the 
groups and similar post-operative ICU and hospital 
stays. PH in the context of transplantation for cirrhosis 
does often cause a need for blood product requirement 
with tendency to bleed from the high pressure portal 
circulation or the coagulopathy associated with 
cirrhosis. This however did not appear the case in this 
cohort.
There are shortcomings however of this retro-
spective study that should be noted with the main 
one the perceived small numbers of patients over a 
long-period of time. It could be argued that in PCLD 
studies large cohorts are not a regular finding but our 
numbers are comparable if not larger then already 
published series[35-43]. In a multicentre European study 
only 58 patients were gained from 75 sites (0.77 per 
site)[14] thus making our cohort a relatively fair one 
for a single centre. To answer the question in a more 
robust manner, larger multicentre databases could 
be generated or analysed with well defined criteria 
for clinically apparent PH to replicate our study on a 
larger setting. Another criticism may be the apparent 
lack of portal pressure studies not a routine practice in 
our centre however the difficulties of this have been 
mentioned previously. Another criticism may be the 
amalgamation of those patients with ascites along with 
those with other features as mentioned above of PH. 
Without HVPG measurements in this group, we think it 
is difficult to tease out specific mechanisms of ascites 
formation in this cohort of patients. Where possible, 
patients protein levels of ascites were checked how-
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ever was not always commonplace over the whole 
12 years of this study, and patients with ascites due 
to PCLD can have a mixed picture when analysing 
protein content as mentioned[34,44]. By grouping 
these together who have clinically significant ascites 
(thus impaired quality of life and function) who often 
required large volume paracentesis (with the potential 
for introduction of infection) we included them in 
our cohort as they may have had worse clinical 
outcomes. However even when this was done, both 
the PH group and non-PH group had similar outcomes 
with regards to survival and with operative/post 
ICU spell parameters. Also irrespective of the actual 
pathophysiological mechanism of ascites formation, 
once present and is not managed by conventional 
therapies, LT assessment would be considered in our 
centre due to the effects on the patient’s quality of life. 
The study period was conducted before the advent 
of high resolution volumetric studies in our institution 
hence we did not comment on liver volumes or those 
of kidneys retrospectively, and their role in predicting 
outcome peri- or post-transplantation from our retro-
spective data set. Also owing to the retrospective 
nature of the data there was no data available on 
advanced nutritional aspects of the patients such as 
actual sarcopenic measurements with CT[45] something 
that is now practiced in our centre. With either ascites 
or pure weight-related effect of the liver cysts, weight 
would not be an accurate measurement for such a 
cohort thus not commented upon. Data was also not 
retrospectively available if women (the majority of our 
cohort) were on the contraceptive oral contraceptive 
pill (COCP). The presence of PCLD has been shown to 
be related to the COCP usage in patients with PCKD[46]. 
Another area to comment is the lack of validated 
symptom questionnaires in our study to assess 
improvements with transplantation. Kirchner et al[29] 
showed there was indeed a symptomatic improvement 
in domains related to health post-LT, however moving 
forward looking at symptom assessment improvement 
via validated questionnaires between groups with PH 
and not would be interesting. A final note is caution to 
the estimated 15-year post-transplantation survivals 
with no obvious difference found between the groups 
(P = 0.138). In a recent study from Neijenhuis et al[47] 
a disease specific questionnaire was developed and 
validated in a European and United States cohort. 
Moving forward, this questionnaire could be used in 
prospective studies involving the PH-component of 
PCLD.
In conclusion, this retrospective single-centre study 
has shown that clinically apparent PH in patients listed 
for LT is common, however also our data suggests 
that PH may not impact on wait-list and peri-/post-
operative outcomes in our cohort of patients studied. 
To our knowledge this is the 1st study to assess a 
PCLD cohort in such a manner. The advent of PH 
and the complications in the PCLD cohort should 
be remembered by physicians and surgeons alike 
especially when patients are being assessed for liver 
transplantation, however does not appear clinically 
apparent PH affects outcome once the decision has 
been made to transplant such patients, especially in 
the hands of skilled surgeons. 
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